Table 2 Contingency table analysis of baseline levels of biomarkers and their value in predicting disease control (complete or partial response, or stable disease > 12 weeks) vs. progressive disease with sunitinib treatment
| Â | VEGF-A | VEGF-C | sVEGFR-2 | sVEGFR-3 | sKIT |
|---|---|---|---|---|---|
Area under ROC curve, % | 77.3 | 87.0 | 53.9 | 55.8 | 51.3 |
ROC-derived cut-point (pg/mL) | 137.6 | 941.8 | 7,416 | 61,600 | 46,635 |
Fisher's exact P-value | 0.0078 | 0.0012 | 0.1107 | 0.090 | 0.6887 |
Relative risk | 2.571 | 4.714 | 1.950 | 1.929 | 1.273 |
Sensitivity | 0.500 | 0.857 | 0.643 | 0.429 | 0.500 |
Specificity | 1.000 | 0.818 | 0.727 | 0.909 | 0.636 |
Accuracy | 0.720 | 0.840 | 0.680 | 0.640 | 0.560 |
Positive predictive value | 1.000 | 0.857 | 0.750 | 0.857 | 0.636 |
Negative predictive value | 0.611 | 0.818 | 0.615 | 0.556 | 0.500 |